Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease

Autor:	Ome Kolsoum Nasir Shoeibi, Mehran Mahdavi Roshan, Abbas Yadegar, Mohammad Abdehagh, Hamidreza Houri, Mohammad Reza Zali, Hamid Asadzadeh Aghdaei, Masoumeh Azimirad, Banafsheh Nadalian, Fahimeh Azimirad, Shabnam Shahrokh, Meysam Olfatifar
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	medicine.medical_specialty genetic structures medicine.drug_class Procalcitonin level Antibiotics IBD flare Disease Infectious and parasitic diseases RC109-216 Gastroenterology Inflammatory bowel disease Procalcitonin Medical microbiology Clostridioides Internal medicine parasitic diseases medicine Humans Univariate analysis Receiver operating characteristic Clostridioides difficile business.industry Research Inflammatory Bowel Diseases medicine.disease bacterial infections and mycoses digestive system diseases ROC curve analysis CD Predictive biomarker Infectious Diseases Clostridioides difficile infection Clostridium Infections Biomarker (medicine) business hormones hormone substitutes and hormone antagonists
Zdroj:	BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021) BMC Infectious Diseases
ISSN:	1471-2334
Popis:	Background Clostridioides difficile infection (CDI) is a major cause of morbidity among patients with inflammatory bowel disease (IBD). Diagnostic biomarkers for early detection of CDI are needed in clinical practice. The relationship between serum procalcitonin and CDI in IBD patients has not been investigated so far. Therefore, we aimed to evaluate the usefulness of measuring serum procalcitonin level to detect CDI in patients with the flare of IBD. Methods One hundred twenty patients with IBD were enrolled in this study. Bacterial identification was performed using standard microbiological and molecular methods. The serum procalcitonin levels were measured in all patients. Receiver operating characteristic (ROC) curve analysis was applied to assess the value of procalcitonin for the prediction of CDI among IBD patients. Results The median serum procalcitonin level was significantly increased in IBD patients with CDI compared to non-CDI IBD patients (0.69 ng/mL vs 0.32 ng/mL). In univariate analysis, log10 procalcitonin was associated with CDI (OR 2.81, 95% CI 1.54–4.09, P-value 10 procalcitonin, age, hospitalization, type of IBD, duration of the disease, and antibiotic usage, procalcitonin showed a robust association with CDI (OR 4.59, 95% CI 2.49–6.70, P-value Conclusions Our results indicate that procalcitonin level can be a good candidate biomarker for assessing the CDI in IBD patients. Further studies are required to decipher whether procalcitonin can predict CDI therapy or its recurrence.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142d1f2c1329f263e7ad39a59fe4d302 https://doaj.org/article/fc366e0986534b4192c6b3b4c871b31e Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.